Alopecia areata clinical trials

Explore recruiting alopecia areata clinical trials.

Recruiting alopecia areata studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alopecia areata trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Severe Alopecia Areata

Germany, Belgium, Poland, Italy, Portugal, Croatia +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, randomized, double-blind, placebo-controlled, parallel group, 3-arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata

Italy, Netherlands, Czechia, Romania, Germany, France +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2B, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of Rezpegaldesleukin in the treatment of severe to very severe alopecia areata in adult patients (Rezolve AA)

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

B7981032 - A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

Germany, Spain, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

I4V-MC-JAIO: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to less than 18 Years of Age with Alopecia Areata

France, Poland, Spain, Hungary, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Italy, France, Czechia, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Alopecia areata trials by city

Alopecia areata in Toronto Alopecia areata in Vancouver Alopecia areata in Montreal Alopecia areata in Calgary Alopecia areata in Edmonton Alopecia areata in Ottawa Alopecia areata in Winnipeg Alopecia areata in Quebec City Alopecia areata in Hamilton Alopecia areata in Kitchener Alopecia areata in London Alopecia areata in Halifax Alopecia areata in New York Alopecia areata in Los Angeles Alopecia areata in Chicago Alopecia areata in Houston

Other conditions

Osteoarthritis Knee osteoarthritis Osteoporosis Sjogren's syndrome Scleroderma Fibromyalgia Psoriasis Eczema (atopic dermatitis) Acne Vitiligo Hidradenitis suppurativa Rosacea Endometriosis Uterine fibroids Menopause Infertility Erectile dysfunction Enlarged prostate (BPH) Breast cancer Prostate cancer Lung cancer Non-small cell lung cancer Colorectal cancer Pancreatic cancer